Furthermore, our work also provides strong evidence for clinical strategies that combine thalidomide with other inhibitors of ER stress, the inflammatory response, and the TLR4-NF-κB pathway to increase the efficacy and therapeutic range available for silicosis patients. This evidence concerns the gene NFKB1 and silicosis.